Please login to the form below

Not currently logged in
Email:
Password:

rare diseases

This page shows the latest rare diseases news and features for those working in and with pharma, biotech and healthcare.

Sanofi sells European generics to Advent for $2.4bn

Sanofi sells European generics to Advent for $2.4bn

The restructuring has already seen it bolster its pipeline in rare diseases with the acquisitions of Bioverativ for $11.6bn and Ablynx for 3.9bn after missing out on earlier bids ... Just this month, for example, GlaxoSmithKline divested its rare disease

Latest news

More from news
Approximately 98 fully matching, plus 242 partially matching documents found.

Latest Intelligence

  • Accelerating diagnosis in rare disease Accelerating diagnosis in rare disease

    Accelerating diagnosis in rare disease. Timely diagnosis in rare disease is one of the fundamental unmet needs for patients, healthcare professionals (HCPs) and biopharma. ... However, as referring and prescribing doctors in rare disease can be small in

  • Accelerating diagnosis in rare disease Accelerating diagnosis in rare disease

    Accelerating diagnosis in rare disease. Timely diagnosis in rare disease is one of the fundamental unmet needs for patients, healthcare professionals (HCPs) and biopharma. ... However, as referring and prescribing doctors in rare disease can be small in

  • Deal Watch January 2018

    Sanofi was also interested in caplacizumab, which fits not only with its rare disease focus but also enhances its portfolio of products for rare blood diseases coming from its acquisition of ... Takeda moves in neurodegenerative diseases and stem cell

  • Finding the patient voice Finding the patient voice

    rheumatoid arthritis, oncology, psychiatry, cardiovascular diseases, rare diseases etc.

  • A catalyst for change A catalyst for change

    The rule may be relaxed when it relates to applications for drugs of critical and rare diseases and paediatric medications, provided that the market currently lacks effective treatments. ... If the drug is an innovative drug, a drug used for rare diseases

More from intelligence
Approximately 17 fully matching, plus 62 partially matching documents found.

Latest appointments

  • Sobi poaches Pfizer’s Fredrick Wetterlundh Sobi poaches Pfizer’s Fredrick Wetterlundh

    supporting our organisation and our journey to become a global leader in rare diseases.”.

  • emotive bolsters client services team emotive bolsters client services team

    During her six years at Chameleon, she was responsible for medical communications acitivites in various therapy areas including diabetes, cardiology, immunology, gastroenterology and rare diseases.

  • Hansa Medical poaches Vifor Pharma’s CEO Hansa Medical poaches Vifor Pharma’s CEO

    Wiinberg concluded: “Søren’s strong track record of managing the development, launch and growth of biopharmaceuticals globally for the treatment of rare diseases and kidney diseases greatly matches Hansa Medical’s

  • Therachon poaches Shire’s Aled Williams Therachon poaches Shire’s Aled Williams

    Williams has more than 25 years’experience in healthcare and pharmaceuticals and most recently he served as vice president and global strategy head for rare gastrointestinal diseases at Shire. ... We believe his considerable leadership experience in

  • Open Health creates new role Open Health creates new role

    Open Health creates new role. Gavin Jones joins the agency as its director of rare disease. ... Jones will work in close partnership with all of the Open Health agencies, driving their existing and future partnerships with customers working in rare

More from appointments
Approximately 1 fully matching, plus 48 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 13 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

Transforming healthcare through effective collaboration. Making work to feel proud of. www.dovetailstrategies.com...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics